Searchable abstracts of presentations at key conferences in endocrinology

ea0011p392 | Diabetes, metabolism and cardiovascular | ECE2006

Testosterone replacement therapy reduces insulin resistance, and improves glycaemic control in hypogonadal men with Type 2 diabetes

Kapoor D , Goodwin E , Channer KS , Jones TH

Type 2 diabetes mellitus is associated with increased prevalence of low serum testosterone levels in men [1]. Testosterone levels in men are known to be positively correlated with insulin sensitivity and negatively with visceral obesity. We performed a double blind placebo controlled crossover study to determine the effect of testosterone treatment on insulin resistance and glycaemic control in 24 hypogonadal men (10 patients treated with insulin) above age of 30 with Type 2 d...

ea0009p2 | Diabetes and metabolism | BES2005

Rosiglitazone increases testosterone levels in hypogonadal men with Type 2 diabetes

Kapoor D , Goodwin E , Channer K , Jones T

Type 2 diabetes mellitus is associated with increased incidence of low serum testosterone levels in men. Testosterone is known to be positively correlated with insulin sensitivity. Rosiglitazone is an insulin sensitizing agent that reduces insulin resistance by binding to PPAR gamma receptor. The purpose of this study was to determine the effect of Rosiglitazone on testosterone levels in hypogonadal men with Type 2 diabetes.This study was approved by BDG...